uniQure (NASDAQ:QURE) Shares Purchased by Invesco Ltd.

Invesco Ltd. grew its position in shares of uniQure (NASDAQ:QURE) by 453.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 613,601 shares of the biotechnology company’s stock after acquiring an additional 502,684 shares during the quarter. Invesco Ltd. owned about 1.26% of uniQure worth $10,836,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of QURE. Sanders Morris Harris LLC lifted its position in uniQure by 50.0% in the 4th quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company’s stock valued at $1,803,000 after purchasing an additional 34,034 shares during the last quarter. Franklin Resources Inc. acquired a new position in shares of uniQure during the third quarter worth approximately $7,360,000. Oppenheimer & Co. Inc. acquired a new position in shares of uniQure during the fourth quarter worth approximately $320,000. Palumbo Wealth Management LLC bought a new position in uniQure in the 4th quarter worth approximately $437,000. Finally, Raymond James Financial Inc. acquired a new stake in uniQure in the 4th quarter valued at approximately $1,951,000. Institutional investors own 78.83% of the company’s stock.

uniQure Price Performance

Shares of NASDAQ:QURE opened at $14.39 on Wednesday. The company has a market capitalization of $778.17 million, a PE ratio of -2.90 and a beta of 0.42. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The stock has a fifty day moving average of $11.91 and a 200-day moving average of $11.40. uniQure has a one year low of $3.73 and a one year high of $19.18.

Insider Transactions at uniQure

In other news, CFO Christian Klemt sold 2,916 shares of the firm’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total value of $33,009.12. Following the completion of the sale, the chief financial officer now owns 155,168 shares of the company’s stock, valued at $1,756,501.76. This trade represents a 1.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Matthew C. Kapusta sold 26,727 shares of the company’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total value of $285,978.90. Following the transaction, the chief executive officer now directly owns 571,188 shares in the company, valued at $6,111,711.60. The trade was a 4.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 90,830 shares of company stock valued at $961,401 over the last three months. Company insiders own 4.74% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $70.00 price target on shares of uniQure in a research note on Monday. StockNews.com upgraded shares of uniQure to a “sell” rating in a research report on Tuesday, March 11th. Chardan Capital started coverage on shares of uniQure in a research note on Tuesday, April 1st. They set a “buy” rating and a $38.00 target price on the stock. Wells Fargo & Company reduced their price target on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a research note on Friday, February 28th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $24.00 price objective on shares of uniQure in a research note on Tuesday, January 21st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $38.80.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.